Laksmi Wulandari, Edward Pandu Wiriansya

Abstract views = 352 times | views = 282 times


EGFR-TKI is the first-line therapy for EGFR-mutant patients. Nevertheless, patients will have disease progression (median PFS 10 – 12 months) due to resistance. The treatment options are still limited in developing countries for such cases, thus double-platinum chemotherapy is the next option. Although IMPRESS study reported no difference in terms of PFS and OS between double-platinum alone and double-platinum plus EGFR-TKI, several local studies reported benefit of continuing EGFR-TKI in combination with double-platinum chemotherapy (treatment beyond progression). This study aimed to compare chemotherapy effects of double-platinum plus EGFR-TKI versus double-platinum alone on patients with NSCLC progression after EGFR-TKI treatment. This was an analytical descriptive study using prospective cohort design, involving 30 patients with disease progression following EGFR-TKI treatment that met inclusion criteria in Dr. Soetomo Hospital. Subjects were divided into two groups: arm A (double-platinum plus EGFR-TKI) and arm B (double-platinum alone). Subjects were observed until 4 cycles of double-platinum chemotherapy. Subjective response (body weight and EQ5D questionnaire) was analyzed, chest CT scans were evaluated using RECIST criteria, and adverse effects were monitored. This study was conducted in accordance with GCP principles and has received ethics certificate from Dr. Soetomo Hospital ethics committee (No. 08/Panke.KKE/I/2017). The results showed that subject characteristics between two arms were insignificantly different (p=0.05). The most common EGFR mutation was exon 21 (50% on arm A and 60% on arm B). Chi square was tested on subjective response parameter (EQ5D (p=0.483)). T2 free sample was tested on semi-subjective parameter (body weight (p=1.00)). Comparison test on both groups after cycle 2 and 4 showed p value=0.05. Statistical test on adverse effect between both groups showed p value=0.526. As a conclusion, there was no significant difference between double-platinum and double-platinum plus EGFR-TKI on patients who had disease progression following EGFR-TKI treatment.


NSCLC; EGFR-TKI; disease progression; double-platinum

Full Text:



American Cancer Society (2016). Cancer facts & figures 2016. Atlanta: American Cancer Society, 1-64

American Cancer Society (2013). What is non-small cell lung cancer? Atlanta: American Cancer Society, 1-82.

American Thoracic Society/European Respiratory Soci-ety (1997). Pretreatment evaluation of non-small-cell lung cancer. Am J Respir Crit Care Med 156, 320-332

Bethune G, Bethune D, Ridgway N, Xu Z (2010). Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J Thorac Dis 2, 48-51

Ettinger DS, Wood DE, Akerley W, et al (2015). Non-small cell lung cancer version 3. National Compre-hensive Cancer Network Clinical Practice Guideline in Oncology

Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM (1996). Patient perception of the side effects of cancer chemotherapy. Annals of Oncology 7, 189-95

INFODATIN (2015). Stop kanker. Pusat Data dan Informasi Kementerian Kesehatan RI

Lin Y, Wang X, Jin H (2014). Review article; EGFR TKI resistance patients: mechanism and strategies. Am J Cancer Res 4, 411-35

Lynch TJ, Bell DW, Sordella R, et al (2004). Activating mutations in the epidermal growth factor recep¬tor underlying responsiveness of non-small- cell lung cancer to gefitinib. N Engl J Med 350, 2129-2139

Mok TS, Wu YL, Thongprasert S, et al (2009). Gefitinib or carboplatin-paclitaxel in pulmonary ade-nocarcinoma. N Engl J Med 36, 947–57

Murray (2005). Bronchogenic carcinoma. In: Mason RJ ed. Murray and Nadel's Textbook Of Respiratory Medicine. 4th ed. Philadelphia, Elsevier Saunders, p 1357-82

Paez J (2004). EGFR mutations in lung cancer: corelation with clinical response to gefitinib therapy. Science 304, 1497-1500

Pao W, Miller V, Zakowski M, et al (2004). EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci 101, 13306-13311

Sachs S, Bilfinger VT (2005). The impact of posi-tronemosion tomography on clinical decision making in university-based multidisciplinary lung cancer practice. Chest 128, 698-708

Soria JC, Wu Y, Nakagawa K, et al (2015). Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. The Lancet Oncology 16, 990-998

Sun J, Ohashi K, Pao W (2013). Characterizing acquir-ed resistance to egfr tyrosine kinase inhibitors in an EGFR mutant lung adenocarcinoma cell line. Engi-neering and Natural sciences 9, 1-7

Zhang Y, Sheng J, Kang S (2014). Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a metaanalysis. Plos one 9, 1-9


  • There are currently no refbacks.

Copyright (c) 2017 Folia Medica Indonesiana

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.




View My Stats

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License